文献速递类风湿关节炎脊柱关节炎其他结缔组织病

乌帕替尼在类风湿关节炎、银屑病关节炎、强直性脊柱炎和特应性皮炎中超过15000患者年的安全性特征

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
PubMed 文献 · RMD Open · 2023-01-01

该分析汇总乌帕替尼15 mg及30 mg(仅特应性皮炎)治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎和特应性皮炎临床试验的安全性数据,共6991例患者、15425患者年暴露,总体耐受性良好,不同疾病间安全性特征差异可能反映患者特征不同。

要点

  • 任何治疗中出现的不良事件发生率在不同疾病间相似(205.5-278.1/100患者年)。
  • 类风湿关节炎和银屑病关节炎患者中带状疱疹、非黑色素瘤皮肤癌和肌酸磷酸激酶升高发生率高于阳性对照药。
  • 严重治疗中出现的不良事件在类风湿关节炎和银屑病关节炎患者中数值上更高。

核心结论

  • 乌帕替尼总体耐受性良好,观察到的安全性特征差异可能反映类风湿关节炎、银屑病关节炎、强直性脊柱炎和特应性皮炎人群患者特征不同。

研究设计与样本

  • 分析截至2021年6月30日乌帕替尼15 mg和30 mg(仅特应性皮炎)治疗类风湿关节炎、银屑病关节炎、强直性脊柱炎和特应性皮炎的临床试验安全性数据,部分类风湿关节炎和银屑病关节炎研究纳入阿达木单抗和甲氨蝶呤作为阳性对照。
  • 分析纳入6991例至少接受一剂乌帕替尼的患者(类风湿关节炎n=3209;银屑病关节炎n=907;强直性脊柱炎n=182;特应性皮炎n=2693),代表15425患者年暴露(最大暴露时长2.75-5.45年)。

主要发现

  • 任何治疗中出现的不良事件发生率为205.5-278.1/100患者年,导致停药的治疗中出现的不良事件发生率为4.5-5.4/100患者年,不同疾病间相似。
  • 严重治疗中出现的不良事件在类风湿关节炎和银屑病关节炎患者中数值上更高。
  • 类风湿关节炎和银屑病关节炎人群中,带状疱疹(1.6-3.6/100患者年)、非黑色素瘤皮肤癌(0-0.8/100患者年)和肌酸磷酸激酶水平升高(4.4-7.9/100患者年)发生率高于阳性对照药。
  • 死亡(0-0.8/100患者年)、严重感染(0-3.9/100患者年)、主要不良心血管事件(0-0.4/100患者年)、静脉血栓栓塞(<0.1-0.4/100患者年)和恶性肿瘤(0.3-1.4/100患者年)发生率在强直性脊柱炎和特应性皮炎中通常最低。
  • 仅特应性皮炎患者中观察到痤疮发生率增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD). METHODS: Safety data from clinical trials of upadacitinib 15 mg and upadacitinib 30 mg (AD only) for treating RA, PsA, AS and AD as of 30 June 2021 were analysed; some RA and PsA studies included adalimumab and methotrexate as active comparators. Treatment-emergent adverse events (TEAEs) were presented by disease as exposure-adjusted event rates per 100 patient years (E/100 PY). RESULTS: The analysis included 6991 patients (RA, n=3209; PsA, n=907; AS, n=182; AD, n=2693) who received at least one dose of upadacitinib, representing 15 425 PY of exposure (maximum duration 2.75-5.45 years) across diseases. Rates (E/100 PY) of any TEAE (205.5-278.1) and TEAE leading to discontinuation (4.5-5.4) were similar across diseases; serious TEAEs were numerically higher in patients with RA and PsA. Rates of herpes zoster (1.6-3.6), non-melanoma skin cancer (0-0.8) and elevations in creatine phosphokinase levels (4.4-7.9) were higher with upadacitinib than with active comparators in the RA and PsA populations. Deaths (0-0.8), serious infections (0-3.9), major adverse cardiovascular events (0-0.4), venous thromboembolism (<0.1-0.4) and malignancies (0.3-1.4) were observed, with rates generally lowest in AS and AD. Increased rates of acne were observed in patients with AD only. CONCLUSIONS: Findings from this analysis demonstrate that upadacitinib is generally well tolerated with observed differences in safety profiles likely reflective of varying patient characteristics across RA, PsA, AS and AD populations. TRIAL REGISTRATION NUMBERS: NCT02675426, NCT02706951, NCT02706847, NCT02629159, NCT02706873, NCT03086343, NCT03104374, NCT03104400, NCT03178487, NCT03569293, NCT03568318 and NCT03607422.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023. PMID: 36754548. doi:10.1136/rmdopen-2022-002735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。